Cipla Limited
CIPLA
Classificação em ações
#1821
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Preço da ação
$14.48
Valor de mercado
$11.70B
Variação (1 dia)
-0.93%
Variação (1 ano)
-23.40%
País
IN
Negociar Cipla Limited (CIPLA)
Categoria
Healthcare
Receita da Cipla Limited (CIPLA)
Receita em Jun 2026 TTM: $3.11B
De acordo com os últimos relatórios financeiros da Cipla Limited, a receita atual da empresa (TTM) é $3.11B. Em 2024, a empresa obteve uma receita de $3.06B um aumento em relação a a receita do ano 2023, que foi de $2.75B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Cipla Limited de 2004 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $3.11B | -2.49% |
| 2025 | $3.19B | 4.10% |
| 2024 | $3.06B | 11.57% |
| 2023 | $2.75B | -4.01% |
| 2022 | $2.86B | 9.48% |
| 2021 | $2.61B | 15.20% |
| 2020 | $2.27B | -3.55% |
| 2019 | $2.35B | 1.32% |
| 2018 | $2.32B | 4.96% |
| 2017 | $2.21B | 8.09% |
| 2016 | $2.04B | 12.47% |
| 2015 | $1.82B | -3.94% |
| 2014 | $1.89B | 24.22% |
| 2013 | $1.52B | 10.05% |
| 2012 | $1.38B | 4,184.62% |
| 2011 | $32.31M | -97.29% |
| 2010 | $1.19B | 22.13% |
| 2009 | $977.12M | -2.50% |
| 2008 | $1.00B | 26.35% |
| 2007 | $793.17M | 21.93% |
| 2006 | $650.54M | 30.23% |
| 2005 | $499.54M | 17.71% |
| 2004 | $424.38M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 112.67% |
IN
|
